아폴로믹스 (APLM)

Apollomics Inc Stock (APLM) dropped by 43.24% from $1.75 to $0.9933 in the trading on Monday October 23, 2023. The reason why APLM stock down today is due to the presentation of vebreltinib efficacy and safety data. Apollomics announced the vebreltinib efficacy and safety data from the KUNPENG clinical trial at ESMO 2023 in NSCLC patients with MetEx14 skipping mutation, achieving an overall response rate (ORR) of 75%.